Brain cancer patients who received this pain medication lived longer, study shows

Print Close
By Melissa Rudy
Published May 21, 2025
Glioblastoma, the most aggressive and deadly type of brain cancer, is known to have a very poor prognosis — but a new study suggests that a pain-relieving drug could extend survival.
Researchers at Mass General Brigham have found that an already-approved medication — a pain reliever and anti-seizure medication called gabapentin — has been linked to improved survival in patients with glioblastoma.
The findings were published in Nature Communications last week.
MICHAEL BOLTON HAD STRANGE SYMPTOMS BEFORE BRAIN CANCER DIAGNOSIS: 'SOMETHING'S WRONG'
Inspired by previous mouse studies that showed gadapentin's potential in targeting tumors, the researchers studied the medical outcomes of nearly 700 patients with glioblastoma.
Many of them had already been taking gabapentin to alleviate nerve pain, according to a press release from MGB.
The patients who were taking the drug survived four months longer than those who were not — 16 months compared to 12 months — which was described as "statistically significant."
"Ultimately, our goal was to highlight the emerging role of cancer neuroscience in GBM progression and emphasize the importance of exploring creative strategies to therapeutically target this evolving neural-tumor axis," lead author Joshua Bernstock, MD, PhD, a clinical fellow in the Department of Neurosurgery at Brigham and Women's Hospital, told Fox News Digital.
BREAST CANCER DRUG COULD HELP PROLONG SURVIVAL FOR CHILDREN WITH BRAIN TUMORS, STUDY FINDS
The team was surprised by the survival benefit, Bernstock noted.
"It's always incredible to see a hypothesis come to life," he said. "I was also really pleased to see the decrease in serum TSP-1 levels in the UCSF cohort, potentially positioning it as a biomarker of response."
Based on the initial findings, Bernstock reached out to researchers at the University of California, San Francisco (UCSF) to study more glioblastoma patients.
Among the 379 patients at USCF, the same outcome was observed — the ones who were taking gabapentin lived 20.8 months on average, compared to 14.7 months for those not taking the drug.
"There have been very few advances in survival for GBM patients since the early 2000s."
"Across both cohorts (1,072 patients total), gabapentin use was consistently associated with a statistically significant improvement in survival," Bernstock told Fox News Digital.
The researchers also noticed that the gadapentin group had lower levels of a protein called TSP-1, which is found in the blood serum, a finding that "needs further investigation."
"There have been very few advances in survival for GBM patients since the early 2000s," Bernstock said in the release. "We need to think more creatively about the emerging biology in these tumors and how to target them." What to know about gadapentin
The U.S. Food and Drug Administration (FDA) initially approved gadapentin in December 1993 to treat seizure activity in adults; the approval was extended to include children in 2000.
Two years later, the agency approved gadapentin for nerve pain following shingles, according to the agency.
The drug is often prescribed for off-label use to treat a range of pain conditions, studies show.
Some of the more common side effects of gadapentin include fatigue, headache, dizziness, fever, nausea and vomiting, memory loss, trouble speaking, weight gain, vision problems, movement problems and recurring infections, according to Cleveland Clinic.
Certain medications may interact with gadapentin. Patients should speak with a doctor if they experience severe or persistent side effects, experts recommend. Potential limitations and next steps
The study did have some limitations, chiefly that it is retrospective and was not controlled.
"While the findings are promising, the study is retrospective — patients were not given gabapentin in a controlled, randomized manner to directly assess its effects," Bernstock told Fox News Digital.
"As such, larger prospective clinical trials are needed to validate these results and to further investigate the role of gabapentin and TSP-1 in GBM progression."
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Bernstock said he is "cautiously optimistic" by the findings.
"While gabapentin is FDA-approved and generally well-tolerated, it's not appropriate to change clinical practice based on these findings alone without a controlled study, something our collaborators at UCSF are working on," he said.
"It's not appropriate to change clinical practice based on these findings alone without a controlled study."
"That said, in GBM patients who develop neuropathic pain or seizures post-craniotomy, there may be a rationale to consider gabapentin more readily than other agents."
For more Health articles, visit www.foxnews.com/health
Glioblastoma — described by Bernstock as "a relentlessly progressive and nearly universally fatal disease" — is the most common type of primary brain cancer, according to Mayo Clinic.
The disease claims the lives of around 14,500 Americans each year. The five-year survival rate is just 6.9%. Print Close
URL
https://www.foxnews.com/health/brain-cancer-patients-who-received-pain-medication-lived-longer-study-shows

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Vogue

27 minutes ago

• Vogue

EMDR: The Therapy Treatment That Miley Cyrus Says Saved Her Life

Anxiety can hinder so much of everyday life, but there are many helpful and safe ways to cope. For Miley Cyrus, she credits a specific type of therapy that helped her with stage fright and what she says also saved her life: EMDR. 'It's so weird because it's like watching a movie in your mind, but it's different than dreaming. You're kind of more in yourself, but still in another place of consciousness that's kind of hard to describe unless you've been in that hypnotic state,' the 32-year-old singer recently said in an interview with The New York Times. EMDR, more formally known as Eye Movement Desensitization and Reprocessing, is a psychotherapy technique that treats trauma-related stress and other mental health issues such as depression, anxiety, panic, grief, loss, and substance disorders. Developed by psychologist Francine Shapiro, PhD, in 1987, it has since been used to help adults (and even children). Cyrus goes on to explain in the interview that her therapist encouraged her to explore different points in her life that matched the anxiety she feels when she would go sing on stage. After finding herself on a mountaintop in a place where she experienced a lot of trauma, she was surrounded by nature and people—her grandma, her mom, her current boyfriend, her as a little child, and even her dog—who have brought her peace and love. When they all grabbed her hand to play Ring Around the Rosie, she came out of that vision feeling renewed. 'I've never had stage fright again,' she says. How does it work? EMDR involves reprocessing traumatic memories or stressful events using bilateral stimulation. Elizabeth Ochoa, PhD, chief psychologist at Mount Sinai-Behavioral Health Center, explains that you'll be asked to recall an emotion, an image, or words that are linked to that traumatic event while a form of bilateral stimulation is being administered by a clinician. The stimulation can include rapid eye movements, during which a person tracks the movements of a finger, ball, or some sort of stimulus with their eyes, tapping, or auditory cues. The goal, Ochoa says, is to reduce distress related to that painful memory. Who is it for? Ochao says that EMDR is perfect for those who are experiencing depression, anxiety, panic, or other emotional distress whenever a traumatic memory is triggered. If this is something that happens frequently enough over a long period of time and it starts to hinder how you live out your day to day life, she says this might be a treatment to consider. The benefits of EMDR Studies show that those who use EMDR can reap the same benefits as those who use years of psychotherapy, just in a shorter amount of time. The idea is that EMDR can help the mind recover from psychological trauma by removing mental blocks that stop the healing, similar to how the body recovers from physical trauma. 'The brain's information processing system naturally moves toward mental health. If the system is blocked or imbalanced by the impact of a disturbing event, the emotional wound festers and can cause intense suffering. Once the block is removed, healing resumes,' writes the EMDR Institute on its site. 'Using the detailed protocols and procedures learned in EMDR training sessions, clinicians help clients activate their natural healing processes.' The downsides of EMDR EMDR can be quite triggering at first. Ochao says that uncomfortable feelings or distressing thoughts, feelings, and even dreams will emerge as you're reprocessing these traumatic events. Those who are not ready to face those painful feelings may want to look for a gentler treatment option. EMDR is not for those who have personality disorders, diagnosed mental illnesses, or severe psychiatric disorders. She adds that this treatment is not suitable for ongoing trauma that is currently happening in your present life. 'In a general sense, for EMDR to be safely utilized, the patient needs to have sufficient emotional coping skills, distress tolerance, and stability to manage the emotional distress that will emerge during treatment safely,' she says. What to Expect During a Session There are eight phases in a single EMDR session. Ochao explains that the initial phase will focus on identifying the memory that is causing all the trauma. The following phase will try to desensitize that memory, using the same bilateral stimulation techniques. Once that memory is neutralized, she says the focus will shift to instilling positive beliefs. The EMDR Institute breaks it down even further like this:

Yahoo

27 minutes ago

• Yahoo

Health insurers vow to speed approval of medical care

UnitedHealthcare , Kaiser Permanente and other major U.S. health insurers say they want to make it faster and easier for patients to obtain care. Health Insurance Plans (AHIP), a trade association that represents the health insurance industry, announced Monday that some of its biggest members are taking steps to streamline "prior authorization" — industry jargon for the process by which health care providers obtain approval from patients' insurance carriers to deliver care. Prior authorization requests can be time-consuming for doctors, resulting in frustrating delays for patients in obtaining essential medical care. According to a survey from the American Medical Medical Association, physicians' offices spend an average of 12 hours per week seeking approval for services from insurers, administrative hurdles that critics say takes time away from providing care. As part of the new agreement, participating insurers have committed to a series of steps they say will speed up the sluggish process. That includes creating a standardized system for submitting prior authorization online, reducing the amount of claims subject to prior authorization and ramping up real-time responses to requests. Such changes are scheduled to take effect in 2026 and 2027. "The health care system remains fragmented and burdened by outdated manual processes, resulting in frustration for patients and providers alike," AHIP CEO Mike Tuffin said in a statement. "Health plans are making voluntary commitments to deliver a more seamless patient experience and enable providers to focus on patient care, while also helping to modernize the system." Shawn Martin, CEO of the American Academy of Family Physicians, said in a statement that the insurance industry initiative is a "step in the right direction," but that the real test will be the impact it has on the experiences of patients and physicians. Dozens of insurers signed onto the commitment, including a number of state Blue Cross and Blue Shield plans and some Medicare and Medicaid plans. In all, AHIP says the joint effort to improve prior authorization could benefit more than 250 million Americans. The signatories include: AmeriHealth Caritas Arkansas Blue Cross and Blue ShieldBlue Cross of IdahoBlue Cross Blue Shield of AlabamaBlue Cross Blue Shield of ArizonaBlue Cross and Blue Shield of HawaiiBlue Cross and Blue Shield of Kansas Blue Cross and Blue Shield of Kansas CityBlue Cross and Blue Shield of LouisianaBlue Cross Blue Shield of MassachusettsBlue Cross Blue Shield of MichiganBlue Cross and Blue Shield of MinnesotaBlue Cross and Blue Shield of NebraskaBlue Cross and Blue Shield of North CarolinaBlue Cross Blue Shield of North DakotaBlue Cross & Blue Shield of Rhode IslandBlue Cross Blue Shield of South CarolinaBlueCross BlueShield of TennesseeBlue Cross Blue Shield of WyomingBlue Shield of CaliforniaCapital Blue CrossCapital District Physicians' Health Plan, Inc. (CDPHP)CareFirst BlueCross BlueShieldCenteneThe Cigna GroupCVS Health AetnaElevance HealthExcellus Blue Cross Blue ShieldGeisinger Health PlanGuideWell Mutual Holding CorporationHealth Care Service CorporationHealthfirst (New York)Highmark Blue Cross Blue Shield of New JerseyHumana Independence Blue CrossIndependent HealthKaiser PermanenteL.A. Care Health PlanMolina HealthcareNeighborhood Health Plan of Rhode IslandPoint32HealthPremera Blue CrossRegence BlueShield, Regence BlueShield of Idaho, Regence BlueCross BlueShield of Oregon, Regence BlueCross BlueShield of Utah, Asuris Northwest Health, BridgeSpan HealthSCAN Health PlanSummaCareUnitedHealthcare Wellmark Blue Cross and Blue Shield Kidney dialysis industry accused of maximizing profits over patients Pentagon officials reveal new details about U.S. strikes on Iran's nuclear sites Netanyahu reacts to U.S. strikes on Iranian nuclear sites

Bloomberg

32 minutes ago

• Bloomberg

Medicaid Cuts Will Hurt Nearly Half of America's Kids

Republican lawmakers claim their proposal to cut hundreds of billions of dollars from Medicaid is designed to protect the country's most vulnerable — that by focusing on work requirements, they're simply eliminating waste from the bloated program and ensuring the money goes to those who truly need it. In reality, anyone who relies on public insurance could be affected, including about 37 million kids, nearly half of all American children.